Home
Healthcare
Summary
While Aurora Cannabis faces headwinds in the domestic market, the company's business in Europe has continued to grow H1-2027.
The company's attractive valuation and strong balance sheet have attracted takeover interest from U.S. competitor Curaleaf.
In response, ACB launched a review of strategic alternatives which resulted in a superior offer from domestic competitor Organigram.
In my view, the Organigram offer delivers better value and greater flexibility for shareholders. As a result, Aurora Cannabis shareholders should consider voting for the agreement.
With the company's shares trading close to Organigram's offer, I am downgrading Aurora Cannabis stock from "Buy" to "Hold" while increasing my price target from US$4.80 to US$5.50.
I do much more than just articles at Value Investor's Edge: Members get access to model portfolios, regular updates, a chat room, and more.…